Literature DB >> 14991402

Opposing regulation of cell proliferation by retinoic acid and the serotonin2B receptor in the mouse frontonasal mass.

N Bhasin1, A-S LaMantia, J M Lauder.   

Abstract

Development of the frontonasal mass (FNM), branchial arches, heart, and limbs depends on neural crest-mediated epithelial-mesenchymal (E-M) interactions. Teratogenesis by retinoic acid (RA) or blockade of serotonergic (5-HT) signaling by the pan-5-HT(2) receptor antagonist, ritanserin, perturbs development of these embryonic structures. In both cases, resulting phenotypes include forebrain and olfactory placode anomalies, malformations of the face, eye and lens, as well as posterior neural tube and cardiac defects. Similar sites of malformations, together with the presence of RA response elements in the 5-HT(2B) receptor promoter, have led to the suggestion that a negative regulatory relationship may exist between RA and 5-HT(2)-mediated 5-HT signaling at sites of E-M interaction (Choi et al. 1997); however, another possibility is that RA and 5-HT act independently as opposing signals to regulate development of common embryonic targets. Together with recent evidence for opposite effects on chondrogenic differentiation in hindlimb micromass cultures (Bhasin et al. 2003a), results of the present study raise the possibility that these pathways may act as opposing signals for common targets in the mouse embryo. The RA receptors, co-factors and metabolic enzymes, and 5-HT(2B) receptors were found to be are coordinately expressed at sites of E-M interaction, including the FNM, in the embryonic day (E)10.5 mouse. Cell proliferation experiments using [(3)H]thymidine incorporation demonstrated that RA or activation of 5-HT(2B) receptors caused opposite effects in FNM explants, namely stimulation or inhibition of cell proliferation, respectively, 5-HT(2B) receptor activation did not appreciably alter patterning in FNM explants. While RA has been shown to regulate lateral patterning in the FNM (LaMantia et al. 2000), 5-HT(2B) receptor activation did not alter patterning in FNM explants. Quantification of 5-HT(2B) receptor transcripts by real-time PCR provided no evidence of negative regulation of 5-HT(2B) receptor expression by RA in FNM explants, although preliminary studies using in situ hybridization had suggested that this was a possibility in both explants and RA teratogenized embryos. Future studies using quantitative PCR may still show this to be the case in teratogenized embryos. Together with the finding of coordinate expression of 5-HT(2B )receptors and RA signaling molecules, results of the present study suggest that RA, and 5-HT mediated by 5-HT(2B )receptors, may act as opposing signals to regulate cell proliferation during craniofacial development in the mouse embryo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991402     DOI: 10.1007/s00429-004-0380-7

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  4 in total

1.  The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation.

Authors:  C Collet; C Schiltz; V Geoffroy; L Maroteaux; J-M Launay; M-C de Vernejoul
Journal:  FASEB J       Date:  2007-09-10       Impact factor: 5.191

2.  Protein kinase C{gamma} mediates regulation of proliferation by the serotonin 5-hydroxytryptamine receptor 2B.

Authors:  Mira M Wouters; Jaime L Roeder; Vivek S Tharayil; Jennifer E Stanich; Peter R Strege; Sha Lei; Michael R Bardsley; Tamas Ordog; Simon J Gibbons; Gianrico Farrugia
Journal:  J Biol Chem       Date:  2009-06-16       Impact factor: 5.157

3.  Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.

Authors:  Baoman Li; Shiquen Zhang; Hongyan Zhang; Weiwei Nu; Liping Cai; Leif Hertz; Liang Peng
Journal:  Psychopharmacology (Berl)       Date:  2008-08-29       Impact factor: 4.530

4.  Regulatory mechanism of CCN2 production by serotonin (5-HT) via 5-HT2A and 5-HT2B receptors in chondrocytes.

Authors:  Ayaka Hori; Takashi Nishida; Shogo Takashiba; Satoshi Kubota; Masaharu Takigawa
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.